Hemophilia B

Study of AAV5-hFIX in Severe or Moderately Severe Haemophilia B

NCT05360706 | PHASE 1 | OBSERVATIONAL

This is an open-label, extension study enrolling patients who have successfully completed all assessments in Study CT-AMT-060-01 (Years 1-5). Assessment phase will begin at Visit 36 (the first clinical visit in this extension study, approximately 5.5 years after the initial dosing visit Study CT-AMT-060-01) and go to Visit 45 (10-years post-dosing in Study CT-AMT-060-01).

6 Sites

9 Participants

Recruiting

18 Years to 55 Years

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

Find closest sites:

SUBMIT

Vivantes Klinikum im Friedrichshain

Berlin,Germany

Universitaetsklinikum Frankfurt Klinikum der Johann Wolfgang Goethe Universitaet

Frankfurt,Germany

Amsterdam UMC Locatie AMC

Amsterdam,Netherlands

Groningen UMC

Groningen,Netherlands

Erasmus MC

Rotterdam,Netherlands

Universitair Medisch Centrum Utrecht

Utrecht,Netherlands

Study Eligibility Criteria

Inclusion Criteria

* Subjects with congenital hemophilia B who completed Study CTAMT-060-01
* Able to provide informed consent following receipt of verbal and written information about the trial.

Exclusion Criteria

* Enrolled subjects will have already been assessed based on the exclusion criteria for Study CT-AMT-060-01.

Additional Studies

Additional studies can be found at ClinicalTrials.gov